Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Research Institute on Aging, The New Jewish Home, New York, New York.
J Am Geriatr Soc. 2019 Oct;67(10):2058-2064. doi: 10.1111/jgs.16081. Epub 2019 Jul 22.
To describe patterns of antihypertensive medication treatment in hypertensive nursing home (NH) residents with and without dementia and determine the association between antihypertensive treatment and outcomes important to individuals with dementia.
Observational cohort study.
All US NHs.
Long-term NH residents treated for hypertension in the second quarter of 2013, with and without moderate or severe cognitive impairment, as defined by the NH Minimum Data Set (MDS) Cognitive Function Scale.
The primary exposure was intensity of antihypertensive treatment, as defined as number of first-line antihypertensive medications in Medicare Part D dispensing data. The outcome measures were hospitalization, hospitalization for cardiovascular diseases using Medicare Hierarchical Condition Categories, decline in physical function using the MDS Activities of Daily Living (ADLs) scale, and death during a 180-day follow-up period.
Of 255 670 NH residents treated for hypertension, 117 732 (46.0%) had moderate or severe cognitive impairment. At baseline, 54.4%, 34.3%, and 11.4% received one, two, and three or more antihypertensive medications, respectively. Moderate or severe cognitive impairment (odds ratio [OR] = 0.80 vs no or mild impairment; P < .0001), worse physical function (OR = 0.64 worst vs best tertile; P < .0001), and hospice or less than a 6-month life expectancy (OR = 0.80; P < .0001) were associated with receipt of fewer antihypertensive medications. Increased intensity of antihypertensive treatment was associated with small increases in hospitalization (difference per additional medication = 0.24%; 95% confidence interval = 0.03%-0.45%) and cardiovascular hospitalization (difference per additional medication = 0.30%; 95% confidence interval = 0.21%-0.39%) and a small decrease in ADL decline (difference per additional medication = -0.46%; 95% confidence interval = -0.67% to -0.25%). There was no significant difference in mortality (difference per additional medication = -0.05%; 95% confidence interval = -0.23% to 0.13%).
Long-term NH residents with hypertension do not experience significant benefits from more intensive antihypertensive treatment. Antihypertensive medications are reasonable targets for deintensification in residents in whom this is consistent with goals of care. J Am Geriatr Soc 67:2058-2064, 2019.
描述患有和不患有痴呆症的高血压疗养院(NH)居民的降压药物治疗模式,并确定降压治疗与痴呆症患者相关的重要结局之间的关联。
观察性队列研究。
所有美国 NH。
在 2013 年第二季度接受高血压治疗且有和无中度或重度认知障碍的长期 NH 居民,认知障碍按照 NH 最低数据集(MDS)认知功能量表定义。
主要暴露因素为降压治疗的强度,定义为医疗保险部分 D 配药数据中一线降压药物的数量。结局指标包括住院、使用医疗保险分层疾病类别进行心血管疾病住院治疗、MDS 日常生活活动(ADL)量表评估的身体功能下降以及 180 天随访期间的死亡。
在接受高血压治疗的 255670 名 NH 居民中,117732 名(46.0%)患有中度或重度认知障碍。基线时,分别有 54.4%、34.3%和 11.4%的患者接受了一种、两种和三种或更多种降压药物。中度或重度认知障碍(比值比[OR] = 0.80 与无或轻度障碍;P<.0001)、身体功能更差(OR = 0.64 最差与最佳三分位;P<.0001)和临终关怀或预期寿命不足 6 个月(OR = 0.80;P<.0001)与接受的降压药物较少相关。增加降压治疗强度与住院治疗(每增加一种药物差异=0.24%;95%置信区间=0.03%-0.45%)和心血管疾病住院治疗(每增加一种药物差异=0.30%;95%置信区间=0.21%-0.39%)的小幅度增加以及 ADL 下降的小幅度减少(每增加一种药物差异=-0.46%;95%置信区间=-0.67%至-0.25%)相关。死亡率无显著差异(每增加一种药物差异=-0.05%;95%置信区间=-0.23%至 0.13%)。
患有高血压的 NH 长期居民并未从更强化的降压治疗中获得显著益处。在符合护理目标的情况下,降压药物是在这些患者中进行减药治疗的合理目标。